“…70 Brundage et al, as part of the Ontario Practice Guidelines process, also found considerable evidence for the use of dose-escalated EBRT (e.g., doses Ͼ 74 Gy) in the intermediate-risk group. 71 Nilsson et al, using the principles adopted by the Swedish Council of Technology Assessment in Health Care, reached the same conclusion. 72 Kuban et al reported the bFFS of a multiinstitutional cohort of 4839 patients with T1 and T2 prostate carcinoma who were treated with EBRT alone and were followed for a minimum of 5 years.…”